Estrella Immunopharma, Inc. (NASDAQ:ESLA) Short Interest Update

Estrella Immunopharma, Inc. (NASDAQ:ESLA) was the recipient of a large increase in short interest during the month of December. As of December 15th, there was short interest totaling 709,318 shares, an increase of 28.5% from the November 30th total of 551,846 shares. Currently, 4.2% of the company’s shares are sold short. Based on an average daily volume of 147,658 shares, the days-to-cover ratio is presently 4.8 days. Based on an average daily volume of 147,658 shares, the days-to-cover ratio is presently 4.8 days. Currently, 4.2% of the company’s shares are sold short.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on the company. Wall Street Zen upgraded shares of Estrella Immunopharma to a “hold” rating in a report on Saturday, November 22nd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Estrella Immunopharma in a research note on Friday, October 31st. Finally, D. Boral Capital reiterated a “buy” rating and issued a $16.00 price target on shares of Estrella Immunopharma in a report on Monday, November 3rd. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Estrella Immunopharma has an average rating of “Hold” and an average target price of $16.00.

Estrella Immunopharma Stock Up 2.0%

Shares of ESLA opened at $1.56 on Thursday. The company has a 50 day moving average of $1.99 and a two-hundred day moving average of $1.39. Estrella Immunopharma has a twelve month low of $0.73 and a twelve month high of $3.15. The company has a market cap of $58.92 million, a price-to-earnings ratio of -4.59 and a beta of 0.53.

Estrella Immunopharma (NASDAQ:ESLA) last issued its quarterly earnings data on Wednesday, November 12th. The company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.19) by $0.06.

Estrella Immunopharma Company Profile

Estrella Immunopharma, Inc, a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103.